The disposition of roxithromycin, an investigational macrolide antibiotic, was evaluated in 20 subjects, 10 with normal renal function (creatinine clearance [CLCR] of 116 + 17 ml/min [mean + standard deviation]) and 10 with severely impaired renal function (CLCR of 10.2 2.6 ml/min) after a single 300-mg oral dose. Plasma concentration-time data were analyzed in terms of a one-or two-compartment oral absorption model utilizing nonlinear regression analysis. The terminal elimination half-life was significantly prolonged in the group with severely impaired renal function (15.5 4.7 h) compared with that of the group with normal renal function (7.9 2.5 h). Apparent total body clearance was significantly reduced in the renally impaired (25.3 10.5 ml/min) in relation to the group with normal renal function (48.8 11.1 ml/min). The first-order absorption rate constants and apparent volumes of distribution did not differ between the two groups. These data indicate that the disposition of roxithromycin is significantly delayed in subjects with CLcRs of <15 ml/min and suggest that the roxithromycin dosing interval be doubled for these patients.
Roxithromycin is an investigational macrolide antibiotic which is similar to erythromycin in chemical structure and antimicrobial spectrum of activity (1, 5, 10) . Preliminary data for animals and humans suggest that oral roxithromycin administration attains concentrations in plasma higher than those of erythromycin because of acid stability and thus better absorption (13) . Furthermore, the terminal elimination half-life (t1/2.) is 7 to 10 h in subjects with normal renal function compared with about 2 h for erythromycin (13) . Although only 15% of roxithromycin is eliminated renally unchanged, recent data with other compounds have demonstrated marked alterations in nonrenal disposition in the presence of decreased renal function (2) . Therefore, this study was designed to evaluate and compare the dispositions of roxithromycin in subjects with normal and severely impaired renal function.
MATERIAL AND METHODS Twenty subjects 18 years of age or older participated in the study after granting written informed consent. The study was approved by our Institutional Review Board. Ten subjects had normal renal function (24-h ambulatory creatinine clearance [CLCRI of .90 ml/min), and ten subjects had chronic renal failure, with CLCRs of <15 ml/min, but were not yet receiving dialysis therapy.
Prior to study entry, each participant underwent a complete medical history, physical examination, hematological and biochemical screening profile, 24-h ambulatory CLCR determination, urinalysis, electrocardiogram, and chest X ray.
Patients with a history of gastrointestinal, cerebrovascular, respiratory, or hepatic disease or a known allergy to macrolide antibiotics were excluded from the study. None 
RESULTS
There were no significant differences in any demographic parameters other than renal function between the two treatment groups (Table 1 ). The decline in the postabsorptive roxithromycin plasma concentration for the subjects with normal renal function was best described in all cases by a one-compartment first-order oral absorption model (Fig. 1 ). An absorption lag time of 0.21 ± 0.035 h (range, 0.15 to 0.23 h) was apparent in 5 of the 10 subjects.
The decline in the postabsorptive roxithromycin plasma concentration for the renally impaired subjects was best described for 9 of the 10 subjects by a one-compartment first-order oral absorption model and for 1 subject by a two-compartment first-order oral absorption model (patient 11). An average absorption time lag of 0.31 ± 0.23 h (range, 0.17 to 0.67 h) was observed for 4 of the 10 renally impaired subjects.
No significant differences in Cm., Tms, V/F, and Ka were observed between the two study groups ( Table 2) . The tl2,, of roxithromycin was significantly prolonged in the renally impaired subjects, 15.5 ± 4.7 h compared with 7.9 ± 2.5 h in the subjects with normal renal function. The CLp/F of roxithromycin was significantly lower in the renally impaired, 25.3 ± 10.5 ml/min compared with that in the subjects with normal renal function, 48.8 ± 11.1 ml/min. Both CLR and CLNR were significantly lower in the renally impaired subjects. The mean cumulative urinary excretion of roxithromycin over 48 h in both study groups is depicted in Fig. 2 . Approximately 40 mg of roxithromycin, or 13% of the administered dose, was recovered in the urine of the subjects with normal renal function, compared with about 5 mg, or 2% of the administered dose, in the urine of the renally impaired subjects.
All subjects tolerated the single-oral-dose administration of roxithromycin without adverse clinical effects or clinically important changes in laboratory tests or physical examination.
DISCUSSION
This study characterized the pharmacokinetics of roxithromycin in subjects with severely impaired renal function and subjects with normal renal function after the administration of a single oral dose. No significant difference in Ka' Cm,x, or Tma, was observed between the two groups of subjects, suggesting that renal insufficiency does not change the absorption of roxithromycin. While plasma protein binding studies were not done, protein binding has been reported to be about 90%, mostly to a,-acid glycoprotein (13) . Pa (13) . The Tmax and t112, of roxithromycin were 1.93 and 10.4 h, respectively, which are consistent with the findings of the present study (13) .
After multiple oral doses (150 mg every 12 h for 3 days) to six healthy males, the tl12, of roxithromycin was 13.2 + 2.9 h (range, 9.7 to 18.5 h) (13) . Although this t112, is more prolonged than that found in the present study, a smaller number of subjects and a more sensitive bioassay were used.
Possible explanations for this longer tl12, include an ability to detect lower roxithromycin plasma concentrations longer or nonlinear pharmacokinetics with this total daily dose (11) . The V/F was not determined, and the authors stated that the CLp could not be accurately measured.
There is only one other report of roxithromycin disposition in subjects with renal failure, in which a single oral dose of 150 mg was given to 12 healthy subjects and 12 subjects with renal failure (CLCR, 4.4 to 71.7 ml/min). The Cm,, t4/2p, and AUCO_72 of roxithromycin were significantly higher in the renally impaired subjects than in the normal subjects, Urinary excretion generally plays a minor role in the clearance of roxithromycin, with only about 13% of an oral dose being recovered in the urine. Fecal excretion of unaltered drug is the major route of elimination for roxithromycin, although metabolism to at least three inactive metabolites does occur (11) . While the effect of renal disease on the disposition of renally eliminated drugs has been well recognized, renal disease may also alter the CLNR of drugs (2, 8) .
For example, the CLNR of cefotaxime was found to be significantly impaired, compared with that in normal subjects, in subjects with severe renal disease not yet receiving dialytic therapy (8) . This study demonstrates decreased clearance, both renal and nonrenal, of roxithromycin in severe renal disease.
Perhaps the most compelling argument for dosage adjustment of roxithromycin for subjects with renal disease is its chemical and pharmacological similarity to erythromycin, which has been demonstrated to be ototoxic, especially when dosage correction is not used in subjects with renal disease (4, 7; J. P. Mery and A. Kanfer, Letter, N. Engl. J. Med. 301:944, 1979). The pharmacokinetics of erythromycin are known to be altered in chronic renal failure; the bioavailability, V, and tl/2,3 are all increased, necessitating dosage reduction in renal disease (6, 7, 12) . From a clinical viewpoint, erythromycin-induced ototoxicity has been associated with elevated erythromycin concentrations in serum (7; Mery and Kanfer, Letter). Ototoxicity has not been reported with roxithromycin; however, the recognition of erythromycin-induced deafness was not initially described. Hence, dosage reduction with roxithromycin is justified for safety reasons, since accumulation of roxithromycin occurs in patients with CLCRs of <15 ml/min.
The use of roxithromycin in antimicrobial therapy will generally be in the outpatient treatment of diseases now being treated with erythromycin, namely infections of the upper respiratory tract and skin structure infections (10) . For organisms frequently implicated in these infections (e.g., Branhamella catarrhalis, Legionella pneumophila, Neisseria gonorrhoeae, Streptococcus pneumoniae, and Mycoplasma pneumoniae), roxithromycin MICs are 0.8 to 1.6 ,ug/ml for 90% of strains tested (1, 5) . Concentrations of roxithromycin in plasma remained greater than this range for at least 24 h in subjects with normal renal function and for at least 48 h in subjects with renal impairment.
A dosing regimen of 150 mg of roxithromycin orally every 12 h for the normal group of subjects studied would be expected to produce at steady state maximal and minimal concentrations in plasma of 6.6 and 2.3 pug/ml, respectively. In contrast, a regimen of 150 mg of roxithromycin orally every 24 h in the group with severe renal disease would be expected to yield maximal and minimal concentrations of 6.6 and 2.3 ,ug/ml in plasma.
In summary, the disposition of roxithromycin is significantly altered in patients with severe renal insufficiency (CLCR, <15 ml/min). Thus, it is recommended that a doubling of the roxithromycin dosing interval be considered for this patient population.
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